These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 30882371)

  • 1. Restoring mitofusin balance prevents axonal degeneration in a Charcot-Marie-Tooth type 2A model.
    Zhou Y; Carmona S; Muhammad AKMG; Bell S; Landeros J; Vazquez M; Ho R; Franco A; Lu B; Dorn GW; Wang S; Lutz CM; Baloh RH
    J Clin Invest; 2019 Mar; 129(4):1756-1771. PubMed ID: 30882371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitochondrial Dysfunction and Pharmacodynamics of Mitofusin Activation in Murine Charcot-Marie-Tooth Disease Type 2A.
    Franco A; Dang X; Zhang L; Molinoff PB; Dorn GW
    J Pharmacol Exp Ther; 2022 Nov; 383(2):137-148. PubMed ID: 36507849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complementation between mouse Mfn1 and Mfn2 protects mitochondrial fusion defects caused by CMT2A disease mutations.
    Detmer SA; Chan DC
    J Cell Biol; 2007 Feb; 176(4):405-14. PubMed ID: 17296794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Finding a new balance to cure Charcot-Marie-Tooth 2A.
    Iwata K; Scorrano L
    J Clin Invest; 2019 Mar; 129(4):1533-1535. PubMed ID: 30882369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Burst mitofusin activation reverses neuromuscular dysfunction in murine CMT2A.
    Franco A; Dang X; Walton EK; Ho JN; Zablocka B; Ly C; Miller TM; Baloh RH; Shy ME; Yoo AS; Dorn GW
    Elife; 2020 Oct; 9():. PubMed ID: 33074106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitofusin 1 overexpression rescues the abnormal mitochondrial dynamics caused by the Mitofusin 2 K357T mutation in vitro.
    Stavropoulos F; Georgiou E; Schiza N; Bell S; Baloh RH; Kleopa KA; Sargiannidou I
    J Peripher Nerv Syst; 2023 Sep; 28(3):329-340. PubMed ID: 37220142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitochondrial fusion and function in Charcot-Marie-Tooth type 2A patient fibroblasts with mitofusin 2 mutations.
    Amiott EA; Lott P; Soto J; Kang PB; McCaffery JM; DiMauro S; Abel ED; Flanigan KM; Lawson VH; Shaw JM
    Exp Neurol; 2008 May; 211(1):115-27. PubMed ID: 18316077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitofusin 2 expression dominates over mitofusin 1 exclusively in mouse dorsal root ganglia - a possible explanation for peripheral nervous system involvement in Charcot-Marie-Tooth 2A.
    Kawalec M; Zabłocka B; Kabzińska D; Neska J; Beręsewicz M
    Folia Neuropathol; 2014; 52(4):436-42. PubMed ID: 25574749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined RNA interference and gene replacement therapy targeting MFN2 as proof of principle for the treatment of Charcot-Marie-Tooth type 2A.
    Rizzo F; Bono S; Ruepp MD; Salani S; Ottoboni L; Abati E; Melzi V; Cordiglieri C; Pagliarani S; De Gioia R; Anastasia A; Taiana M; Garbellini M; Lodato S; Kunderfranco P; Cazzato D; Cartelli D; Lonati C; Bresolin N; Comi G; Nizzardo M; Corti S
    Cell Mol Life Sci; 2023 Nov; 80(12):373. PubMed ID: 38007410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MFN1 augmentation prevents retinal degeneration in a Charcot-Marie-Tooth type 2A mouse model.
    Shahin S; Lu B; Zhou Y; Xu H; Chetsawang J; Baloh RH; Wang S
    iScience; 2023 Mar; 26(3):106270. PubMed ID: 36936780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of mitofusin 2(R94Q) in a transgenic mouse leads to Charcot-Marie-Tooth neuropathy type 2A.
    Cartoni R; Arnaud E; Médard JJ; Poirot O; Courvoisier DS; Chrast R; Martinou JC
    Brain; 2010 May; 133(Pt 5):1460-9. PubMed ID: 20418531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Charcot-Marie-Tooth type 2A in vivo models: Current updates.
    Abati E; Rizzuti M; Anastasia A; Comi GP; Corti S; Rizzo F
    J Cell Mol Med; 2024 May; 28(9):e18293. PubMed ID: 38722298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mfn2
    Zhang Y; Ma L; Wang Z; Gao C; Yang L; Li M; Tang X; Yuan H; Pang D; Ouyang H
    Int J Biol Macromol; 2024 Oct; 278(Pt 1):134673. PubMed ID: 39142491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Altered axonal mitochondrial transport in the pathogenesis of Charcot-Marie-Tooth disease from mitofusin 2 mutations.
    Baloh RH; Schmidt RE; Pestronk A; Milbrandt J
    J Neurosci; 2007 Jan; 27(2):422-30. PubMed ID: 17215403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective mitochondrial depletion, apoptosis resistance, and increased mitophagy in human Charcot-Marie-Tooth 2A motor neurons.
    Rizzo F; Ronchi D; Salani S; Nizzardo M; Fortunato F; Bordoni A; Stuppia G; Del Bo R; Piga D; Fato R; Bresolin N; Comi GP; Corti S
    Hum Mol Genet; 2016 Oct; 25(19):4266-4281. PubMed ID: 27506976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A SARM1-mitochondrial feedback loop drives neuropathogenesis in a Charcot-Marie-Tooth disease type 2A rat model.
    Sato-Yamada Y; Strickland A; Sasaki Y; Bloom J; DiAntonio A; Milbrandt J
    J Clin Invest; 2022 Dec; 132(23):. PubMed ID: 36287202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A human mitofusin 2 mutation can cause mitophagic cardiomyopathy.
    Franco A; Li J; Kelly DP; Hershberger RE; Marian AJ; Lewis RM; Song M; Dang X; Schmidt AD; Mathyer ME; Edwards JR; Strong CG; Dorn GW
    Elife; 2023 Nov; 12():. PubMed ID: 37910431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CMT2A-linked MFN2 mutation, T206I promotes mitochondrial hyperfusion and predisposes cells towards mitophagy.
    Das R; Maity S; Das P; Kamal IM; Chakrabarti S; Chakrabarti O
    Mitochondrion; 2024 Jan; 74():101825. PubMed ID: 38092249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MFN2 agonists reverse mitochondrial defects in preclinical models of Charcot-Marie-Tooth disease type 2A.
    Rocha AG; Franco A; Krezel AM; Rumsey JM; Alberti JM; Knight WC; Biris N; Zacharioudakis E; Janetka JW; Baloh RH; Kitsis RN; Mochly-Rosen D; Townsend RR; Gavathiotis E; Dorn GW
    Science; 2018 Apr; 360(6386):336-341. PubMed ID: 29674596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MFN2-related neuropathies: Clinical features, molecular pathogenesis and therapeutic perspectives.
    Stuppia G; Rizzo F; Riboldi G; Del Bo R; Nizzardo M; Simone C; Comi GP; Bresolin N; Corti S
    J Neurol Sci; 2015 Sep; 356(1-2):7-18. PubMed ID: 26143526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.